Bio-Path Holdings
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The last earnings update was 34 days ago. More info.
Add to Portfolio Compare Print
- Bio-Path Holdings has significant price volatility in the past 3 months.
BPTH Share Price and Events
7 Day Returns
1 Year Returns
BPTH Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Bio-Path Holdings (BPTH) | -8.3% | -13.5% | 950.8% | -46.9% | -96.6% | -95.9% |
| US Biotechs | -5.8% | -4.9% | -5.4% | -3.1% | -2.4% | 16.7% |
| US Market | -0.3% | 2% | 8.5% | 7% | 37.7% | 46.8% |
1 Year Return vs Industry and Market
- BPTH underperformed the Biotechs industry which returned -3.1% over the past year.
- BPTH underperformed the Market in United States of America which returned 7% over the past year.
BPTH Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Bio-Path Holdings. This is due to cash flow or dividend data being unavailable. The share price is $19.02.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Bio-Path Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Bio-Path Holdings's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $-14.38 |
| NasdaqCM:BPTH Share Price ** | NasdaqCM (2019-04-18) in USD | $19.02 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 19.22x |
| United States of America Market PE Ratio | Median Figure of 3,081 Publicly-Listed Companies | 18.18x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Bio-Path Holdings.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqCM:BPTH Share Price ÷ EPS (both in USD) = 19.02 ÷ -14.38 |
-1.32x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Bio-Path Holdings is loss making, we can't compare its value to the US Biotechs industry average.
- Bio-Path Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Bio-Path Holdings's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -1.32x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
Not available |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 28 Publicly-Listed Biotechs Companies | 1.77x |
| United States of America Market PEG Ratio | Median Figure of 2,109 Publicly-Listed Companies | 1.56x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Bio-Path Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Bio-Path Holdings's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $1.79 |
| NasdaqCM:BPTH Share Price * | NasdaqCM (2019-04-18) in USD | $19.02 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 416 Publicly-Listed Biotechs Companies | 3.26x |
| United States of America Market PB Ratio | Median Figure of 5,184 Publicly-Listed Companies | 1.91x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqCM:BPTH Share Price ÷ Book Value per Share (both in USD) = 19.02 ÷ 1.79 |
10.62x |
* Primary Listing of Bio-Path Holdings.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Bio-Path Holdings is overvalued based on assets compared to the US Biotechs industry average.
Value checks
We assess Bio-Path Holdings's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Bio-Path Holdings has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
BPTH Future Performance
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bio-Path Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Bio-Path Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Bio-Path Holdings's earnings growth to the United States of America market average as no estimate data is available.
- Unable to compare Bio-Path Holdings's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 18.5% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 15.1% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.4% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | -6 | -9 | |
| 2018-09-30 | 0 | -7 | -9 |
| 2018-06-30 | 0 | -7 | -8 |
| 2018-03-31 | 0 | -8 | -10 |
| 2017-12-31 | 0 | -8 | -8 |
| 2017-09-30 | 0 | -7 | -7 |
| 2017-06-30 | 0 | -8 | -6 |
| 2017-03-31 | 0 | -8 | -5 |
| 2016-12-31 | 0 | -8 | -7 |
| 2016-09-30 | -8 | -7 | |
| 2016-06-30 | -7 | -7 | |
| 2016-03-31 | -6 | -6 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from Bio-Path Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | -14.38 |
| 2018-09-30 | -15.70 |
| 2018-06-30 | -15.11 |
| 2018-03-31 | -18.20 |
| 2017-12-31 | -15.99 |
| 2017-09-30 | -14.91 |
| 2017-06-30 | -13.20 |
| 2017-03-31 | -11.21 |
| 2016-12-31 | -14.56 |
| 2016-09-30 | -14.99 |
| 2016-06-30 | -15.10 |
| 2016-03-31 | -13.28 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Bio-Path Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Bio-Path Holdings's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Bio-Path Holdings has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
BPTH Past Performance
How has Bio-Path Holdings performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Bio-Path Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Bio-Path Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Bio-Path Holdings's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Bio-Path Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | -8.58 | 3.38 | 4.60 | |
| 2018-09-30 | 0.04 | -8.84 | 3.39 | 5.49 |
| 2018-06-30 | 0.04 | -8.23 | 3.55 | 4.73 |
| 2018-03-31 | 0.04 | -9.58 | 3.54 | 5.39 |
| 2017-12-31 | 0.04 | -8.06 | 3.52 | 5.48 |
| 2017-09-30 | 0.01 | -7.27 | 3.44 | 5.04 |
| 2017-06-30 | 0.01 | -6.36 | 3.22 | 5.77 |
| 2017-03-31 | 0.01 | -5.28 | 3.14 | 5.48 |
| 2016-12-31 | 0.01 | -6.75 | 3.01 | 5.47 |
| 2016-09-30 | -6.84 | 2.88 | 5.39 | |
| 2016-06-30 | -6.78 | 2.72 | 4.07 | |
| 2016-03-31 | -5.96 | 2.53 | 3.45 | |
| 2015-12-31 | -5.47 | 2.47 | 3.02 | |
| 2015-09-30 | -5.61 | 2.74 | 2.89 | |
| 2015-06-30 | -5.25 | 2.93 | 2.33 | |
| 2015-03-31 | -5.39 | 3.12 | 2.29 | |
| 2014-12-31 | -4.52 | 2.72 | 1.83 | |
| 2014-09-30 | -3.71 | 2.19 | 1.54 | |
| 2014-06-30 | -3.96 | 2.29 | 1.68 | |
| 2014-03-31 | -3.11 | 1.78 | 1.35 | |
| 2013-12-31 | -3.27 | 1.63 | 1.63 | |
| 2013-09-30 | -2.91 | 1.55 | 1.36 | |
| 2013-06-30 | -2.36 | 0.98 | 1.37 | |
| 2013-03-31 | -2.72 | 0.99 | 1.38 | |
| 2012-12-31 | -2.58 | 0.99 | 1.25 | |
| 2012-09-30 | -2.95 | 0.95 | 1.31 | |
| 2012-06-30 | -2.62 | 1.03 | 0.90 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Bio-Path Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Bio-Path Holdings has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Bio-Path Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Bio-Path Holdings's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Bio-Path Holdings has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
BPTH Health
How is Bio-Path Holdings's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Bio-Path Holdings's finances.
The net worth of a company is the difference between its assets and liabilities.
- Bio-Path Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Bio-Path Holdings has no long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Bio-Path Holdings has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Bio-Path Holdings Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 1.22 | 0.00 | 1.00 |
| 2018-09-30 | 2.99 | 0.00 | 2.29 |
| 2018-06-30 | 4.74 | 0.00 | 2.58 |
| 2018-03-31 | 6.28 | 0.00 | 4.28 |
| 2017-12-31 | 8.07 | 0.00 | 5.97 |
| 2017-09-30 | 6.55 | 0.00 | 4.62 |
| 2017-06-30 | 8.86 | 0.00 | 6.18 |
| 2017-03-31 | 8.09 | 0.00 | 7.11 |
| 2016-12-31 | 8.24 | 0.00 | 9.38 |
| 2016-09-30 | 9.38 | 0.00 | 11.30 |
| 2016-06-30 | 6.33 | 0.00 | 4.22 |
| 2016-03-31 | 8.05 | 0.00 | 6.47 |
| 2015-12-31 | 9.82 | 0.00 | 8.85 |
| 2015-09-30 | 11.19 | 0.00 | 9.85 |
| 2015-06-30 | 12.60 | 0.00 | 11.08 |
| 2015-03-31 | 13.63 | 0.00 | 12.45 |
| 2014-12-31 | 14.92 | 0.00 | 13.86 |
| 2014-09-30 | 16.00 | 0.00 | 14.64 |
| 2014-06-30 | 17.03 | 0.00 | 15.72 |
| 2014-03-31 | 18.18 | 0.00 | 16.82 |
| 2013-12-31 | 4.78 | 0.00 | 3.55 |
| 2013-09-30 | 5.58 | 0.00 | 4.10 |
| 2013-06-30 | 3.48 | 0.00 | 1.93 |
| 2013-03-31 | 1.68 | 0.00 | 0.29 |
| 2012-12-31 | 2.01 | 0.00 | 0.53 |
| 2012-09-30 | 1.80 | 0.00 | 0.33 |
| 2012-06-30 | 1.92 | 0.00 | 0.16 |
- Bio-Path Holdings has no debt.
- Bio-Path Holdings has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Bio-Path Holdings has less than a year of cash runway based on current free cash flow.
- Bio-Path Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.3% each year.
Financial health checks
We assess Bio-Path Holdings's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Bio-Path Holdings has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
BPTH Dividends
What is Bio-Path Holdings's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Bio-Path Holdings
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Bio-Path Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Bio-Path Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 20 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2009 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Bio-Path Holdings has not reported any payouts.
- Unable to verify if Bio-Path Holdings's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Bio-Path Holdings's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Bio-Path Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Bio-Path Holdings has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
BPTH Management
CEO
| COMPENSATION | $671,927 |
| AGE | 69 |
| TENURE AS CEO | 11.3 years |
CEO Bio
Mr. Peter H. Nielsen, MBA, is a Co-Founded Bio-path Holdings, Inc. in 2007 and has been its Chairman, President, Chief Executive Officer, Chief Financial Officer and Treasurer since 2008. Mr. Nielsen licensed technology and targets from The University of Texas, MD Anderson Cancer Center and coordinated preclinical development, optimization and manufacturing of Bio-Path’s lead drug candidate, prexigebersen. Over the next ten years, Mr. Nielsen led the clinical advancement of prexigebersen into Phase II studies, the introduction of additional pipeline candidates and the Company’s public market debut. Mr. Nielsen served as Chief Accounting Officer at Bio-path Holdings, Inc. He co-founded Interpath Pharmaceuticals, Inc. in 2001 and serves as its Chief Executive Officer. He has a broad management background in senior management, leading turnarounds of several large companies. He has experience in finance, product development, cost and investmentanalysis, manufacturing and planning. Mr. Nielsen served as Chief Financial Officer of Omni Energy Services Corp. He worked with several otherbiotech companies developing and executing on strategies for growth and is a Director of Synthecon, Inc. He has been Director of Bio-path Holdings, Inc. since 2008. Mr. Nielsen was a Lieutenant in the U.S. Naval Nuclear Power program where he was Director of the Physics Dept. and was employed at Ford Motor Company inproduct development. He holds engineering, mathematics and M.B.A. finance degrees from the University of California at Berkeley.
CEO Compensation
- Peter's compensation has increased whilst company is loss making.
- Peter's remuneration is higher than average for companies of similar size in United States of America.
Management Team
Peter Nielsen
Co-Founder
$672K
69
11.3 yrs
Douglas Morris
Co-Founder
$91K
62
12.3 yrs
Anthony Price
Director of Finance and Accounting
Alan MacKenzie
Consultant
Thomas Walker
Consultant
Jeffery Lancet
Consultant
Victoria Lake
Regulatory Consultant
Board of Directors Tenure
Average tenure and age of the Bio-Path Holdings board of directors in years:
- The average tenure for the Bio-Path Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors
Peter Nielsen
Co-Founder
$672K
69
11.3 yrs
Douglas Morris
Co-Founder
$91K
62
12.3 yrs
Heath Cleaver
Director
$57K
45
5.2 yrs
Jorge Cortes
Chairman of the Scientific Advisory Board
3.7 yrs
Mark Colonnese
Director
$58K
63
1.8 yrs
D. Hooper
Member of Scientific Advisory Board
2.2 yrs
Paul Aubert
Director
$48K
48
0.3 yrs
Anas Younes
Member of Scientific Advisory Board
0.3 yrs
Jason Fleming
Member of Scientific Advisory Board
0.7 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 23. Jan 19 | Sell | Armistice Capital LLC | Company | 18. Jan 19 | 18. Jan 19 | -64,457 | $2.66 | $-171,643 | ||
Management checks
We assess Bio-Path Holdings's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Bio-Path Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
BPTH News
Simply Wall St News
What Kind Of Investor Owns Most Of Bio-Path Holdings, Inc. (NASDAQ:BPTH)?
The big shareholder groups in Bio-Path Holdings, Inc. … Bio-Path Holdings is a smaller company with a market capitalization of US$39m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company.
Simply Wall St - – Full articleDid Changing Sentiment Drive Bio-Path Holdings's Share Price Down A Disastrous 99%?
We don't think Bio-Path Holdings's revenue of US$37,000 is enough to establish significant demand. … It seems likely some shareholders believe that Bio-Path Holdings has the funding to invent a new product before too long. … Bio-Path Holdings had net cash of just US$1.3m when it last reported (September 2018).
Simply Wall St - – Full articleDoes Bio-Path Holdings, Inc.'s (NASDAQ:BPTH) CEO Salary Reflect Performance?
In 2008 Peter Nielsen was appointed CEO of Bio-Path Holdings, Inc. … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Peter Nielsen's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleBio-Path Holdings Inc (NASDAQ:BPTH): Time For A Financial Health Check
The direct benefit for Bio-Path Holdings Inc (NASDAQ:BPTH), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is BPTH will have to adhere to stricter debt covenants and have less financial flexibility. … Does BPTH's growth rate justify its decision for financial flexibility over lower cost of capital.
Simply Wall St - – Full articleIs Bio-Path Holdings Inc's (NASDAQ:BPTH) CEO Being Overpaid?
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Peter Nielsen's Compensation Compare With Similar Sized Companies. … As you can see, Peter Nielsen is paid more than the median CEO pay at companies of a similar size, in the same market
Simply Wall St - – Full articleHow Financially Strong Is Bio-Path Holdings Inc (NASDAQ:BPTH)?
Bio-Path Holdings Inc (NASDAQ:BPTH), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Is BPTH growing fast enough to value financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.
Simply Wall St - – Full articleHow Should You Think About Bio-Path Holdings Inc's (NASDAQ:BPTH) Risks?
A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … With a beta of 2.76, Bio-Path Holdings is a stock that tends to experience more gains than the market during a growth phase and also a bigger reduction in value compared to the market during a broad downturn. … Based on this beta value, BPTH may be a stock for investors with a portfolio mainly made up of low-beta stocks.
Simply Wall St - – Full articleBio-Path Holdings Inc (NASDAQ:BPTH): Does The -19.42% Earnings Drop Reflect A Longer Term Trend?
View our latest analysis for Bio-Path Holdings Commentary On BPTH's Past Performance For the purpose of this commentary, I like to use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … NasdaqCM:BPTH Income Statement Apr 11th 18 We can further examine Bio-Path Holdings's loss by looking at what the industry has been experiencing over the past few years. … Though Bio-Path Holdings's past data is helpful, it is only one aspect of my investment thesis.
Simply Wall St - – Full articleIs It Time To Buy Bio-Path Holdings Inc (NASDAQ:BPTH)?
Bio-Path Holdings Inc (NASDAQ:BPTH), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the highs of $3.1 and falling to the lows of $1.82. … I find that Bio-Path Holdings’s ratio of 2.78x is trading slightly above its industry peers’ ratio of 2.65x, which means if you buy Bio-Path Holdings today, you’d be paying a relatively fair price for it. … And if you believe Bio-Path Holdings should be trading in this range, then there isn’t really any room for the share price grow beyond what it’s currently trading.
Simply Wall St - – Full articleIs It Time To Buy Bio-Path Holdings Inc (BPTH)?
So, could BPTH still be trading at a low price relative to its actual value? … The stock’s ratio of 3.3x is currently trading slightly below its industry peers’ ratio of 4.9x, which means if you buy BPTH today, you’d be paying a relatively fair price for it. … If you’ve been keeping tabs on BPTH, now may not be the most advantageous time to buy, given it is trading around its fair value.
Simply Wall St - – Full articleBPTH Company Info
Description
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and myelodysplastic syndrome, as well as in Phase IIa clinical trials for the treatment of chronic myeloid leukemia. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Details
| Name: | Bio-Path Holdings, Inc. |
| BPTH | |
| Exchange: | NasdaqCM |
| Founded: | 2007 |
| $47,687,685 | |
| 2,507,239 | |
| Website: | http://www.biopathholdings.com |
| Address: |
Bio-Path Holdings, Inc. 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas, 77401, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqCM | BPTH | Common Stock | Nasdaq Capital Market | US | USD | 15. Feb 2008 | |
| DB | IBPB | Common Stock | Deutsche Boerse AG | DE | EUR | 15. Feb 2008 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/22 00:05 |
| End of day share price update: | 2019/04/18 00:00 |
| Last estimates confirmation: | 2017/03/15 |
| Last earnings filing: | 2019/03/19 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
